Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines for cardiovascular, anti-diabetic, antineoplastic, and orthopedic therapeutic in China. It offers cardiovascular and cerebrovascular products, such as allisartan isoproxil, benazepril hydrochloride, desloratadine, and clopidogrel bisulfate tablets, as well as bivalirudin and pamidronate disodium injections; recombinant SeV-hFGF2/dF Injection for the treatment of diabetic foot disease; and anti-tumor and orthopedics medicines. The company also provides anti-infection products comprising cefonicid sodium, ceftazidime, ceftriaxone sodium, cefonicid sodium, cefminox sodium, cefuroxime sodium, cefepime hydrochloride, and cefodizime sodium injections, as well as azithromycin dispersible and levetiracetam tablets. In addition, it offers biotechnological drugs, such as recombinant protein and monoclonal antibody drugs. Further, the company is involved in import, licensing-in, and licensing-out medicines for Europe markets. The company was founded in 1998 and is headquartered in Shenzhen, China.
Our mission is to advance the frontiers of drug delivery, research and development as well as technology, making available and affordable drugs to people all over the world.
We strive to become a global leader in the biopharmaceutical industry, bringing innovative drug delivery strategies, improved and non-invasive drug therapies and better medications to the world for the advancement of health and wellbeing of humanity.
Mr. Jie Yan (Deputy GM & Non Independent Director)
Mr. Jianfeng Yang (Sec. of the Board of Directors & Non Independent Director)
Ms. Song Ping Zhao (Deputy Gen. Mang.)
Xie Heng M.D., Ph.D. (Chief Medical Officer)
Shenzhen Salubris Pharmaceuticals has earned numerous awards over the years, including the prestigious China High-Tech Enterprise Award, the Pharmaceutical Research and Development Award and the Chinese National Professional Title Award.
